News roundup

Inaphaea BioLabs news roundup: July 2023

This roundup covers our news, updates, and highlights from July.

It has been a particularly busy time for Inaphaea, and we’re looking forward to the lab’s official launch event with BioNow on 26 September, where we hope to see faces old and new. 

To discuss any of our updates, please contact Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea BioLabs, who will be happy to help.

July 2023 news roundup

First external contract win for Inaphaea BioLabs

We were delighted to announce that Inaphaea BioLabs has signed a Master Services Agreement and Project Statement of Work with a UK-based biotech company.

This defined work programme, which involves a multi-stage project and is expected to complete at the end of September 2023, is investigating possible anti-cancer properties of a range of novel molecules using a phenotypic assay and will benefit from the use of patient-derived cells (“PDCs”) from Inaphaea’s biobank, recently acquired from the liquidated assets of Imagen.

In addition, Inaphaea has commenced studies on internal ValiRx assets VAL301 and Cytolytix CLX001, thereby reducing third-party testing costs and reducing potential for delays.

Find out more about the announcement here.

Inaphaea sponsors On Helix

On 6 July, Inaphaea’s Head of Strategic Development, Dr Andrew Carnegie and ValiRx’s CEO Dr Suzy Dilly and Corporate Development Manager Mark Treharne attended On Helix in Cambridge.

The conference, which has become a staple in the life sciences events calendar, addresses the key trends in bio innovation, from developments in life science and technology research, to their translation into new diagnostics, prevention tools or treatments.

As a member of One Nucleus, Inaphaea BioLabs was a sponsor of On Helix and had a booth at the event, which attracted a number of visitors who we enjoyed speaking to about all things cell assays, oncology, and women’s health.

Inaphaea BioLabs launch event

We are now less than two months away from the launch of Inaphaea BioLabs!

On 26 September, we are hosting an event with BioNow to mark Inaphaea’s official launch at MediCity in Nottingham. The afternoon event will include a tour of the labs and the recently acquired assets from Imagen Therapeutics, alongside talks from keynote speakers, networking opportunities, and a buffet lunch.

Register for the event on BioNow’s website here.